Cargando…

Changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study

BACKGROUND: Elevated serum phosphorus concentrations are common among maintenance hemodialysis patients. Protein is a major source of dietary phosphate, but restriction of protein intake can result in hypoalbuminemia and protein-energy wasting. We hypothesized that sucroferric oxyhydroxide (SO), a p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kalantar-Zadeh, Kamyar, Ficociello, Linda H., Parameswaran, Vidhya, Athienites, Nicolaos V., Mullon, Claudy, Kossmann, Robert J., Coyne, Daniel W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820926/ https://www.ncbi.nlm.nih.gov/pubmed/31664928 http://dx.doi.org/10.1186/s12882-019-1582-9

Ejemplares similares

One-Year Historical Cohort Study of the Phosphate Binder Sucroferric Oxyhydroxide in Patients on Maintenance Hemodialysis
por: Kendrick, Jessica, et al.
Publicado: (2019)

Sucroferric Oxyhydroxide in Maintenance Hemodialysis: A Retrospective, Comparative Cohort Study
por: Coyne, Daniel W., et al.
Publicado: (2020)

Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data
por: Coyne, Daniel W., et al.
Publicado: (2017)

Phosphate binder pill burden, adherence, and serum phosphorus control among hemodialysis patients converting to sucroferric oxyhydroxide
por: Gray, Kathryn, et al.
Publicado: (2019)

Serum Phosphorus and Pill Burden Among Hemodialysis Patients Prescribed Sucroferric Oxyhydroxide: One-Year Follow-Up on a Contemporary Cohort
por: Kendrick, Jessica B, et al.
Publicado: (2022)

Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence
por: Coyne, Daniel W., et al.
Publicado: (2022)

A real-world analysis of the influence of age on maintenance hemodialysis patients: managing serum phosphorus with sucroferric oxyhydroxide as part of routine clinical care
por: Rhee, Connie M., et al.
Publicado: (2022)

Slipping Through the Pores: Hypoalbuminemia and Albumin Loss During Hemodialysis
por: Kalantar-Zadeh, Kamyar, et al.
Publicado: (2021)

Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients
por: Floege, Jürgen, et al.
Publicado: (2015)

Efficacy and Safety of Sucroferric Oxyhydroxide and Calcium Carbonate in Hemodialysis Patients
por: Koiwa, Fumihiko, et al.
Publicado: (2017)

Impact of sucroferric oxyhydroxide on the oral and intestinal microbiome in hemodialysis patients
por: Abdelbary, Mohamed M. H., et al.
Publicado: (2022)

Effect of the phosphate binder sucroferric oxyhydroxide in dialysis patients on endogenous calciprotein particles, inflammation, and vascular cells
por: Thiem, Ursula, et al.
Publicado: (2022)

Bicarbonate levels in hemodialysis patients switching from lanthanum carbonate to sucroferric oxyhydroxide
por: Stavroulopoulos, Aristeidis, et al.
Publicado: (2018)

Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric  Oxyhydroxide
por: Cozzolino, Mario, et al.
Publicado: (2014)

Effect of Citrate-Acidified Dialysate on Intact Parathyroid Hormone in Prevalent Hemodialysis Patients: A Matched Retrospective Cohort Study
por: Ficociello, Linda H, et al.
Publicado: (2021)

A comparison between the combined effect of calcium carbonate with sucroferric oxyhydroxide and other phosphate binders: an in vitro and in vivo experimental study
por: Yaguchi, Atsushi, et al.
Publicado: (2019)

The effect of phosphate binder therapy with sucroferric oxyhydroxide on calcification propensity in chronic haemodialysis patients: a randomized, controlled, crossover trial
por: Thiem, Ursula, et al.
Publicado: (2020)

Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide
por: Covic, Adrian C., et al.
Publicado: (2017)

Evaluation of changes in ferritin levels during sucroferric oxyhydroxide treatment
por: Koiwa, Fumihiko, et al.
Publicado: (2018)

Phosphate binding by sucroferric oxyhydroxide ameliorates renal injury in the remnant kidney model
por: Nemoto, Yoshikazu, et al.
Publicado: (2019)

Gut microbiome in hemodialysis patients treated with calcium acetate or treated with sucroferric oxyhydroxide: a pilot study
por: Merino-Ribas, Ana, et al.
Publicado: (2021)

Real-world management of hyperphosphataemia with sucroferric oxyhydroxide: the VELREAL multicentre study
por: Navarro-González, Juan F, et al.
Publicado: (2021)

Safety and efficacy of sucroferric oxyhydroxide in pediatric patients with chronic kidney disease
por: Greenbaum, Larry A., et al.
Publicado: (2020)

The real-world effectiveness of sucroferric oxyhydroxide in European hemodialysis patients: a 1-year retrospective database analysis
por: Ramos, Rosa, et al.
Publicado: (2020)

Real-world safety and effectiveness of sucroferric oxyhydroxide for treatment of hyperphosphataemia in dialysis patients: a prospective observational study
por: Vervloet, Marc G, et al.
Publicado: (2021)

Renoprotective effects of sucroferric oxyhydroxide in a rat model of chronic renal failure
por: Neven, Ellen, et al.
Publicado: (2020)

Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients
por: Shima, Hisato, et al.
Publicado: (2018)

Proton pump inhibitors may hinder hypophosphatemic effect of lanthanum carbonate, but not of ferric citrate hydrate or sucroferric oxyhydroxide, in hemodialysis patients
por: Minakuchi, Hitoshi, et al.
Publicado: (2020)

Drug–drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects
por: Chong, Edward, et al.
Publicado: (2014)

Effectiveness of sucroferric oxyhydroxide in patients on on-line hemodiafiltration in real-world clinical practice: A retrospective study
por: Ferreira, Aníbal, et al.
Publicado: (2019)

Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease–mineral bone disorder parameters in dialysis patients
por: Ketteler, Markus, et al.
Publicado: (2019)

A 6-Month clinical practice pilot study of sucroferric oxyhydroxide on nutritional status in patients on peritoneal dialysis
por: Perez, Luis, et al.
Publicado: (2022)

Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide
por: Cernaro, Valeria, et al.
Publicado: (2016)

Iron kinetics following treatment with sucroferric oxyhydroxide or ferric citrate in healthy rats and models of anaemia, iron overload or inflammation
por: Floege, Jürgen, et al.
Publicado: (2020)

Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure
por: Phan, Olivier, et al.
Publicado: (2015)

Benefits of Incremental Hemodialysis Seen in a Historical Cohort Study
por: Chen, Weisheng, et al.
Publicado: (2021)

Managing Phosphate Burden in Patients Receiving Dialysis: Beyond Phosphate Binders and Diet
por: Kalantar-Zadeh, Kamyar, et al.
Publicado: (2023)

Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland
por: Gutzwiller, Florian S., et al.
Publicado: (2015)

Real-World Performance of High-Flux Dialyzers in Patients With Hypoalbuminemia
por: Zhou, Meijiao, et al.
Publicado: (2021)

Incremental and Once- to Twice-Weekly Hemodialysis: From Experience to Evidence
por: Obi, Yoshitsugu, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_3u21mj4c3jog0pc7hjvkslb37r